BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results

Reuters02-27

Feb 27 (Reuters) - Pacira Biosciences Inc PCRX.O:

PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS
PACIRA BIOSCIENCES FY ADJUSTED EBITDA USD 186.5 MILLION VS. IBES ESTIMATE USD 204 MILLION
PACIRA BIOSCIENCES FY NET INCOME USD 7 MILLION
PACIRA BIOSCIENCES FY ADJUSTED NET INCOME USD 122.3 MILLION VS. IBES ESTIMATE USD 139.8 MILLION
PACIRA BIOSCIENCES INC - OUTLOOK 2026 TOTAL REVENUE OF $745 MILLION TO $770 MLN

Source text: ID:nGNX2vzVBn

Further company coverage: PCRX.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614107051?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 07:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614107051","market":"us","top_or_hot":-1,"title":"BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results</title></head><body><p><span>Feb 27 (Reuters)</span><span> - </span>Pacira Biosciences Inc <span>PCRX.O</span>:</p><ul><li><p>PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS</p></li><li><p>PACIRA BIOSCIENCES FY ADJUSTED EBITDA USD 186.5 MILLION VS. IBES ESTIMATE USD 204 MILLION</p></li><li><p>PACIRA BIOSCIENCES FY NET INCOME USD 7 MILLION</p></li><li><p>PACIRA BIOSCIENCES FY ADJUSTED NET INCOME USD 122.3 MILLION VS. IBES ESTIMATE USD 139.8 MILLION</p></li><li><p>PACIRA BIOSCIENCES INC - OUTLOOK 2026 TOTAL REVENUE OF $745 MILLION TO $770 MLN</p></li></ul><p>Source text: <span>ID:nGNX2vzVBn</span></p><p>Further company coverage: <span>PCRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-27 07:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results</title></head><body><p><span>Feb 27 (Reuters)</span><span> - </span>Pacira Biosciences Inc <span>PCRX.O</span>:</p><ul><li><p>PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS</p></li><li><p>PACIRA BIOSCIENCES FY ADJUSTED EBITDA USD 186.5 MILLION VS. IBES ESTIMATE USD 204 MILLION</p></li><li><p>PACIRA BIOSCIENCES FY NET INCOME USD 7 MILLION</p></li><li><p>PACIRA BIOSCIENCES FY ADJUSTED NET INCOME USD 122.3 MILLION VS. IBES ESTIMATE USD 139.8 MILLION</p></li><li><p>PACIRA BIOSCIENCES INC - OUTLOOK 2026 TOTAL REVENUE OF $745 MILLION TO $770 MLN</p></li></ul><p>Source text: <span>ID:nGNX2vzVBn</span></p><p>Further company coverage: <span>PCRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUABW2MKL:1","article_id":"2614107051","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614107051","pubTimestamp":1772148026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial ResultsFeb 27 (Reuters) - Pacira Biosciences Inc PCRX.O:PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PCRX":"Pacira Pharmaceuticals"},"translate_title":"简报-Pacira Biosciences报告2025年第四季度和全年财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":0.9},"content_text":"BRIEF-Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial ResultsFeb 27 (Reuters) - Pacira Biosciences Inc PCRX.O:PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTSPACIRA BIOSCIENCES FY ADJUSTED EBITDA USD 186.5 MILLION VS. IBES ESTIMATE USD 204 MILLIONPACIRA BIOSCIENCES FY NET INCOME USD 7 MILLIONPACIRA BIOSCIENCES FY ADJUSTED NET INCOME USD 122.3 MILLION VS. IBES ESTIMATE USD 139.8 MILLIONPACIRA BIOSCIENCES INC - OUTLOOK 2026 TOTAL REVENUE OF $745 MILLION TO $770 MLNSource text: ID:nGNX2vzVBnFurther company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614107051","isCrawlerRequest":true}